安进 (AMGN)

货币 USD
361.16
-5.09(-1.39%)
闭盘·
362.00+0.87(+0.24%)
·

安进公司档案

安进公司是一家生物技术公司。该公司探索、开发、制造及销售人类治疗药品。该公司通过人类治疗药品业务运营。该公司销售的药品包括:Neulasta(pegfilgrastim),Aranesp(darbepoetin alfa)及EPOGEN(epoetin alfa)等促红细胞生成剂,Sensipar/Mimpara(cinacalcet),XGEVA(denosumab),Prolia(denosumab),NEUPOGEN(filgrastim),和Vectibix (panitumumab)、Nplate(romiplostim)及Corlanor(ivabradine)等。该公司专注于研发用于治疗肿瘤及血液病、心血管病、炎症、骨骼病、肾脏病及神经疾病等严重疾病的人类药物。该公司研发的处于第III阶段的产品包括用于发作性偏头痛的Erenumab,骨髓增生异常综合征的Aranesp,急性淋巴细胞白血病的BLINCYTO和转移性黑色素瘤的IMLYGIC。

行业
制药
员工
31500
市场
美国

联络信息

地址
One Amgen Center Drive, Thousand Oaks, 91320-1799, United States
电话
805 447 1000
传真
805 447 1010

高管

名称
标题
任期
年龄
Robert A. BradwayChairman & CEO201363
Robert A. EckertLead Independent Director201672
Gregory C. GarlandIndependent Director201369
Ellen J. KullmanIndependent Director201670
Charles M. HolleyIndependent Director201769
Charles Elliott SigalCo-Chair of the Scientific Advisory Board-74
Jonathan S. WeissmanCo-Chair of the Scientific Advisory Board2026-
Tyler E. JacksIndependent Director201265
R. Sanders WilliamsMember of Scientific Advisory Board of Cardiovascular & Metabolic202477
Wanda M. AustinIndependent Director201772
Brian J. DrukerIndependent Director201870
Amy E. MilesIndependent Director202059
S. Omar IshrakIndependent Director202170
S. Gail EckhardtMember of Scientific Advisory Board of Oncology2022-
Michael V. DrakeIndependent Director202274
Diane J. MathisMember of Scientific Advisory Board of Inflammation--
Lillian L. SiuMember of Scientific Advisory Board of Oncology2022-
Emma Guttman-YasskyMember of Scientific Advisory Board of Inflammation2022-
Alexander MarsonMember of Scientific Advisory Board of Inflammation2022-
Alexander RudenskyMember of Scientific Advisory Board of Inflammation2022-
Arlene SharpeMember of Scientific Advisory Board of Inflammation2022-
Dean SheppardMember of Scientific Advisory Board of Inflammation2022-
Maria T. AbreuMember of Scientific Advisory Board of Inflammation2022-
George GeorgiouMember of Scientific Advisory Board of Research Trends & Emerging Technologies202367
Siwen Hu-LieskovanMember of Scientific Advisory Board of Oncology--
Marlene RabinovitchMember of Scientific Advisory Board of Cardiovascular & Metabolic--
Benoit Van den EyndeMember of Scientific Advisory Board of Oncology--
Antoni RibasMember of Scientific Advisory Board of Oncology-59
Robert S. NegrinMember of Scientific Advisory Board of Oncology--
Andrew Mark PardollMember of Scientific Advisory Board of Oncology--
Dirk JägerMember of Scientific Advisory Board of Oncology--
David Alan KassMember of Scientific Advisory Board of Cardiovascular & Metabolic--
Daniel P. KellyMember of Scientific Advisory Board of Cardiovascular & Metabolic--
Thomas QuertermousMember of Scientific Advisory Board of Cardiovascular & Metabolic-74
Peter LibbyMember of Scientific Advisory Board of Cardiovascular & Metabolic-78
Jeffery D. MolkentinMember of Scientific Advisory Board of Cardiovascular & Metabolic--
Daniel Joshua DruckerMember of Scientific Advisory Board of Cardiovascular & Metabolic--
E. Dale AbelMember of Scientific Advisory Board of Cardiovascular & Metabolic--
Frank P. McCormickMember of Scientific Advisory Board of Research Trends & Emerging Technologies-76
David J. AndersonMember of Scientific Advisory Board of Research Trends & Emerging Technologies--
Ronald M. EvansMember of Scientific Advisory Board of Research Trends & Emerging Technologies-76
Mary Earley KlotmanIndependent Director202472
Fabrice AndreMember of Scientific Advisory Board of Oncology--
Randy J. SeeleyMember of Scientific Advisory Board2025-
Viviana GradinaruMember of Scientific Advisory Board of Research Trends & Emerging Technologies2026-
Eran SegalMember of Scientific Advisory Board of Research Trends & Emerging Technologies2026-
Philip ZamoreMember of Scientific Advisory Board of Research Trends & Emerging Technologies2026-
David J. MooneyMember of Scientific Advisory Board of Research Trends & Emerging Technologies2026-
James ZouMember of Scientific Advisory Board of Research Trends & Emerging Technologies2026-
Patrick HsuMember of Scientific Advisory Board of Research Trends & Emerging Technologies2026-
风险批露: 交易股票、外汇、商品、期货、债券、基金等金融工具或加密货币属高风险行为,这些风险包括损失您的部分或全部投资金额,所以交易并非适合所有投资者。加密货币价格极易波动,可能受金融、监管或政治事件等外部因素的影响。保证金交易会放大金融风险。
在决定交易任何金融工具或加密货币前,您应当充分了解与金融市场交易相关的风险和成本,并谨慎考虑您的投资目标、经验水平以及风险偏好,必要时应当寻求专业意见。
Fusion Media提醒您,本网站所含数据未必实时、准确。本网站的数据和价格未必由市场或交易所提供,而可能由做市商提供,所以价格可能并不准确且可能与实际市场价格行情存在差异。即该价格仅为指示性价格,反映行情走势,不宜为交易目的使用。对于您因交易行为或依赖本网站所含信息所导致的任何损失,Fusion Media及本网站所含数据的提供商不承担责任。
未经Fusion Media及/或数据提供商书面许可,禁止使用、存储、复制、展现、修改、传播或分发本网站所含数据。提供本网站所含数据的供应商及交易所保留其所有知识产权。
本网站的广告客户可能会根据您与广告或广告主的互动情况,向Fusion Media支付费用。
本协议的英文版本系主要版本。如英文版本与中文版本存在差异,以英文版本为准。
© 2007-2026 - Fusion Media Limited | 粤ICP备17131071号 | 保留所有权利。